AzTrials
AzTrials

Age-related Macular DegenerationNCT04087356

Age-related Macular Degeneration (AMD) and Cardiovascular Disease

An observational study of Age-related Macular Degeneration and Coronary Artery Disease, run by The New York Eye & Ear Infirmary at 1 site in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The purpose of this research study is to investigate the link between age-related macular degeneration (AMD or ARMD) and coronary artery disease (CAD). Age-related macular degeneration is a medical condition which may result in blurred or no vision in the center of vision. Read more about this study

Who is it for?
Ages 50 years and older
What is being tested?
Blood draw
How many people
200 participants
Where
1 siteUnited States
Study dates
2 Aug 2019to 20 Dec 2020
How long will I take part?
1 Year
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients with AMD with and without RMD

Who may be able to join

  • Clinical diagnosis of age-related macular degeneration in at least one eye.
  • Patients can have unilateral, but not bilateral CNV. In the case of unilateral CNV, the eye without the CNV will be the study eye.
  • Age greater than 50
  • Willing and able to comply with clinic visit and study-related procedures
  • Provide signed informed consent
  • Able to understand and complete study-related questionnaire
  • Be able to tolerate dilating drops

Who cannot join

  • Bilateral CNV
  • Other retinal degenerations and retinal vascular diseases such as diabetic retinopathy or macular edema, prior retinal surgery
  • Pregnant, lactating, or currently expecting a child

Trial locations and contacts

1 site in 1 country.

R. Theodore Smith, MD PhD contact

212-9794579

rolandtheodore.smith@mssm.edu

United States1 site, 1 recruiting
  • New York Eye and Ear Infirmary

    New York, New York, 10003

    Theodore Smith, MD, 212-979-4579, rolandtheodore.smith@mssm.edu

    Theodore Smith, MD

    Recruiting

Other trials in United States

About this study

The purpose of this research study is to investigate the link between age-related macular degeneration (AMD or ARMD) and coronary artery disease (CAD). Age-related macular degeneration is a medical condition which may result in blurred or no vision in the center of vision. Coronary artery disease is a blockage of one or more arteries that supply blood to the heart. The study will specifically look at the macular changes that occur in the retina, which is the sensory membrane that lines the inner surface at the back of the eyeball, and the relationship between coronary heart disease and the risk factors.

Read the detailed description

The treatment of age-related macular degeneration (AMD), the leading cause of blindness in the developed world, is undergoing a revolution. Intraocular injections of medications that can shut down the rapidly destructive "wet" form of the disease have changed this form to a chronic illness. However, vision is still lost. For the early forms of AMD, progression to the advanced "wet" and "dry" forms and severe vision loss is impeded but not stopped by current therapies of oral antioxidants. Thus, a better understanding of early AMD is needed to discover its root causes and provide treatment before irreparable damage is done.

The most important, highest-risk, and least understood form of early AMD is "reticular macular disease" (RMD). RMD is associated with significant progression to advanced AMD, both wet and dry. The lesions of RMD are well seen on the advanced retinal imaging techniques of spectral domain optical coherence tomography (SD-OCT) and scanning laser ophthalmoscopy (SLO). On SLO, RMD presents a pox-like pattern of dark defects SD-OCT provides high-resolution cross-sectional images of the retina, where RMD is seen as a collection of cholesterol-containing deposits, and the choroid, an essential blood supply of the retina, which is thinned and may be damaged in RMD. A unified explanation of these facets of RMD is lacking.

Regarding AMD and systemic diseases, the association between stroke, heart attack and AMD has been studied, but with some conflicting findings. For example, a relationship with heart attack has been established in patients less than age 75, but not in older patients. Where does RMD fit in? At present, no one knows. However, the known facts are these: RMD is associated with decreased longevity, which is not the case with other early forms of AMD. This could happen if RMD and systemic vascular disease co-exist. Finally, there is the very high proportion of women relative to men among older patients with RMD, about 85%. Women develop heart disease later than men and survive heart disease a decade longer on average. It is possible that these diseases both begin earlier in life, with more men dying before reaching older ages and demonstrating RMD. The research team submitting this proposal has preliminary data suggesting that this is in fact the case.

In a small group of subjects 50-75 years old, RMD was detected in a significant proportion of those with CAD compared to those without. Furthermore, in this younger group, the ratio of men to women in the RMD group was equal. The team proposes a large-scale initiative to provide definitive answers to these questions, in collaboration with expert cardiologists and neurologists to document vascular status unequivocally, and utilizing the most advanced retinal imaging available for the detection of RMD. This could lead to greater understanding of all three, stroke, heart attack and AMD, and ultimately better treatment, providing much needed relief to suffering patients and relief to the healthcare burden of an aging population.

Being tested
Blood draw
Medical subject headings
Macular Degeneration, Coronary Artery Disease, Cardiovascular Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Blood drawGenetic

    Blood samples are collected for genetic analysis, looking specifically at serum lipids and the inflammatory biomarker hs-CRP.

Study groups in NCT04087356
Study groupRoleWhat they receive
RMD+ PatientsAge-related macular degeneration patients with reticular macular disease
Receives: Genetic: Blood draw
RMD- PatientsAge-related macular degeneration patients without reticular macular disease
Receives: Genetic: Blood draw

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of CAD+ patients in RMD+ Patients

    Rate of coronary artery disease in age-related macular disease patients with reticular macular disease

    Measured: 6 months

  2. Proportion of CAD+ patients in RMD- Patients

    Rate of coronary artery disease in age-related macular disease patients without reticular macular disease

    Measured: 6 months

Secondary outcomes (5)
  1. Evaluation of CAD risk factors as predictors of RMD status

    Investigating the relationship between AMD/RMD to cardiac risk factors such as tobacco use, hyperlipidemia, elevated C-Reactive protein an inflammatory biomarker, and hypertension.

    Measured: 6 months

  2. Correlation of lipid panels with RMD status

    Measuring the total cholesterol in blood, the standard cholesterol test (called a "lipid panel") measures three specific kinds of fat: Low-density lipoproteins (LDL). High-density lipoproteins (HDL). Triglycerides.

    Measured: 6 months

  3. Correlation of the C-Reactive Protein as an inflammatory biomarker with RMD status

    High sensitivity CRP (hsCRP) blood tests able to measure down to 0.3 mg/L which is necessary in risk assessment for vascular disease.

    Measured: 6 months

  4. Correlation of imaging features with RMD status

    Correlation of presence of soft drusen, geographic atrophy or choroidal neovascularization status in fellow eye, if present, with RMD status

    Measured: 6 months

  5. Correlation of genetic markers with CFHY402H and CFHrs1410996 genotypes, adjusting for AMD grade. These phenotypes may be a marker of genetic susceptibility for patients with RMD status.

    High sensitivity RMD genetic blood test for markers with RMD status

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Sep 2019
  2. Study start2 Aug 2019
  3. Primary completion31 Jan 2020 (estimated)
  4. Study completion20 Dec 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
200 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT04087356
Sponsor's protocol ID
IRB-19-01872
Status last verified
Sep 2019
First submitted
9 Jul 2019
Last updated
12 Sep 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Thomson RJ, Chazaro J, Otero-Marquez O, Ledesma-Gil G, Tong Y, Coughlin AC, Teibel ZR, Alauddin S, Tai K, Lloyd H, Scolaro M, Govindaiah A, Bhuiyan A, Dhamoon MS, Deobhakta A, Narula J, Rosen RB, Yannuzzi LA, Freund KB, Smith RT. SUBRETINAL DRUSENOID DEPOSITS AND SOFT DRUSEN: Are They Markers for Distinct Retinal Diseases? Retina. 2022 Jul 1;42(7):1311-1318. doi: 10.1097/IAE.0000000000003460.

    PubMed 35213528

Questions about this trial

What is this clinical trial studying?

An observational study of Age-related Macular Degeneration and Coronary Artery Disease, run by The New York Eye & Ear Infirmary at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact R. Theodore Smith, MD PhD (212-9794579, rolandtheodore.smith@mssm.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of CAD+ patients in RMD+ Patients (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04087356, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Sep 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in